Podcast
Questions and Answers
Systemic lupus erythematosus (SLE) is a rare autoimmune disease.
Systemic lupus erythematosus (SLE) is a rare autoimmune disease.
False (B)
The most common clinical manifestations of SLE are fatigue, fever, and weight loss.
The most common clinical manifestations of SLE are fatigue, fever, and weight loss.
True (A)
Neurological symptoms, such as seizures and psychosis, are present in 60% of SLE patients.
Neurological symptoms, such as seizures and psychosis, are present in 60% of SLE patients.
True (A)
Cardiovascular diseases are not a common complication of SLE.
Cardiovascular diseases are not a common complication of SLE.
Polyarthritis is a rare manifestation of SLE, occurring in only 10% of patients.
Polyarthritis is a rare manifestation of SLE, occurring in only 10% of patients.
Diagnosing SLE is a straightforward process with clear-cut diagnostic criteria.
Diagnosing SLE is a straightforward process with clear-cut diagnostic criteria.
The 5-year survival rate for patients with SLE is approximately 95%.
The 5-year survival rate for patients with SLE is approximately 95%.
Decreased complement levels are a sign of disease activity in SLE.
Decreased complement levels are a sign of disease activity in SLE.
Antiphospholipid antibodies are associated with a poor prognosis in SLE.
Antiphospholipid antibodies are associated with a poor prognosis in SLE.
Renal failure is the leading cause of death in patients with SLE.
Renal failure is the leading cause of death in patients with SLE.
The goal of SLE treatment is to induce remission of acute flares and then maintain it, as well as prevent organ damage.
The goal of SLE treatment is to induce remission of acute flares and then maintain it, as well as prevent organ damage.
Aggressive therapy with high-dose corticosteroids and a second immunosuppressive agent is recommended for SLE manifestations that are not reversible.
Aggressive therapy with high-dose corticosteroids and a second immunosuppressive agent is recommended for SLE manifestations that are not reversible.
Belimumab is a drug that inhibits B-cell activation and is used in the treatment of Systemic Lupus Erythematosus (SLE).
Belimumab is a drug that inhibits B-cell activation and is used in the treatment of Systemic Lupus Erythematosus (SLE).
Chronic discoid lupus erythematosus (DLE) is a variant of SLE that is limited to the skin and is characterized by circular, scaly, hyperpigmented rashes.
Chronic discoid lupus erythematosus (DLE) is a variant of SLE that is limited to the skin and is characterized by circular, scaly, hyperpigmented rashes.
Immunosuppressive agents like cyclophosphamide and mycophenolate mofetil are used in the treatment of serious kidney and central nervous system (CNS) involvement in SLE.
Immunosuppressive agents like cyclophosphamide and mycophenolate mofetil are used in the treatment of serious kidney and central nervous system (CNS) involvement in SLE.
Neonatal lupus is a condition where the mother's anti-SSA/Ro and anti-SSB/La antibodies affect the fetus, causing skin rash, liver problems, and low blood cell counts, but these symptoms persist throughout the child's life.
Neonatal lupus is a condition where the mother's anti-SSA/Ro and anti-SSB/La antibodies affect the fetus, causing skin rash, liver problems, and low blood cell counts, but these symptoms persist throughout the child's life.
Drug-induced lupus is a variant of SLE characterized by fever, malaise, arthritis/arthralgia, myalgia, serositis, and/or rash, but without kidney or CNS involvement.
Drug-induced lupus is a variant of SLE characterized by fever, malaise, arthritis/arthralgia, myalgia, serositis, and/or rash, but without kidney or CNS involvement.
Hydroxychloroquine, an anti-malaria drug, is used in the treatment of SLE for managing joint pain and skin rashes.
Hydroxychloroquine, an anti-malaria drug, is used in the treatment of SLE for managing joint pain and skin rashes.
